^
    Back
    Association details:
    Biomarker:EML4-ALK gene fusion + EGFR exon 19 deletion + EGFR T790M + EGFR C797G
    Cancer:Lung Adenocarcinoma
    Drug:Erbitux (cetuximab) (EGFR inhibitor) +
    Alunbrig (brigatinib) (EGFR inhibitor, ALK inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2018
    Title:

    Effect of EGFR C797S/G mutation on osimertinib resistance in Chinese patients with non-small-cell lung cancer.

    Published date:
    05/16/2018
    Excerpt:
    Study patients were all advanced lung adenocarcinoma...1 patient had EML4-ALK gene fusion as well as EGFR 19 del, T790M and C797G mutations, progressed with 1 month crizotinib orally, but had partial response with two-cycle of bargatinib plus cetuximab treatment.
    DOI:
    10.1200/JCO.2018.36.15_suppl.e21171